These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 20976449)
1. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Vergati M; Cereda V; Madan RA; Gulley JL; Huen NY; Rogers CJ; Hance KW; Arlen PM; Schlom J; Tsang KY Cancer Immunol Immunother; 2011 Feb; 60(2):197-206. PubMed ID: 20976449 [TBL] [Abstract][Full Text] [Related]
2. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Gulley JL; Arlen PM; Madan RA; Tsang KY; Pazdur MP; Skarupa L; Jones JL; Poole DJ; Higgins JP; Hodge JW; Cereda V; Vergati M; Steinberg SM; Halabi S; Jones E; Chen C; Parnes H; Wright JJ; Dahut WL; Schlom J Cancer Immunol Immunother; 2010 May; 59(5):663-74. PubMed ID: 19890632 [TBL] [Abstract][Full Text] [Related]
3. Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer. Si TG; Wang JP; Guo Z Asian J Androl; 2013 Jul; 15(4):461-5. PubMed ID: 23728588 [TBL] [Abstract][Full Text] [Related]
4. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. Farsaci B; Jochems C; Grenga I; Donahue RN; Tucker JA; Pinto PA; Merino MJ; Heery CR; Madan RA; Gulley JL; Schlom J Int J Cancer; 2014 Aug; 135(4):862-70. PubMed ID: 24474335 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Huen NY; Pang AL; Tucker JA; Lee TL; Vergati M; Jochems C; Intrivici C; Cereda V; Chan WY; Rennert OM; Madan RA; Gulley JL; Schlom J; Tsang KY Int J Cancer; 2013 Jul; 133(2):373-82. PubMed ID: 23319273 [TBL] [Abstract][Full Text] [Related]
6. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Jochems C; Tucker JA; Tsang KY; Madan RA; Dahut WL; Liewehr DJ; Steinberg SM; Gulley JL; Schlom J Cancer Immunol Immunother; 2014 Apr; 63(4):407-18. PubMed ID: 24514956 [TBL] [Abstract][Full Text] [Related]
7. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Tang S; Moore ML; Grayson JM; Dubey P Cancer Res; 2012 Apr; 72(8):1975-85. PubMed ID: 22374980 [TBL] [Abstract][Full Text] [Related]
8. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789 [TBL] [Abstract][Full Text] [Related]
9. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Derhovanessian E; Adams V; Hähnel K; Groeger A; Pandha H; Ward S; Pawelec G Int J Cancer; 2009 Sep; 125(6):1372-9. PubMed ID: 19533748 [TBL] [Abstract][Full Text] [Related]
13. [The phenotype and function of CD4+ CD25+ regulatory T cells in hepatitis B patients]. Fu JL; Xu DP; Shi M; Zhang H; Jin L; Tang ZR; Wang FS Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):642-5. PubMed ID: 17074148 [TBL] [Abstract][Full Text] [Related]
14. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122 [TBL] [Abstract][Full Text] [Related]
15. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Yokokawa J; Cereda V; Remondo C; Gulley JL; Arlen PM; Schlom J; Tsang KY Clin Cancer Res; 2008 Feb; 14(4):1032-40. PubMed ID: 18281535 [TBL] [Abstract][Full Text] [Related]
16. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924 [TBL] [Abstract][Full Text] [Related]
17. Reduced frequency and functional defects of CD4 Luo L; Zeng X; Huang Z; Luo S; Qin L; Li S Reprod Biol Endocrinol; 2020 Jun; 18(1):62. PubMed ID: 32522204 [TBL] [Abstract][Full Text] [Related]
18. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. Fong B; Jin R; Wang X; Safaee M; Lisiero DN; Yang I; Li G; Liau LM; Prins RM PLoS One; 2012; 7(4):e32614. PubMed ID: 22485134 [TBL] [Abstract][Full Text] [Related]
19. Current vaccination strategies for prostate cancer. Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436 [TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]